Jean-Claude Provost

Jean-Claude Provost, MD, joined Lantheus as Interim Chief Medical Officer in April 2022 and was appointed permanently in January 2023. Dr. Provost brings to the Company more than 30 years of experience in the international development of therapeutic drugs and diagnostic agents, including radiopharmaceuticals and contrasts media agents. During his career, he has consistently demonstrated successful management of global research and development of products at all phases, from discovery to post-marketing life cycle management.

Dr. Provost joined Lantheus from his firm, Theranostics Consulting, where he provides research and development, and medical, and strategic consulting services to pharmaceutical and biotechnology companies and investment firms. In this capacity, he has advised Lantheus for the last three years. Previously, he was head of global research and development for GE Healthcare’s pharmaceutical diagnostics division. Prior to his tenure at GE Healthcare, he co-founded Smo-Clinica, a contract research organization that specialized in clinical trial patient recruitment and management. He also held several management and clinical research positions with Pfizer, Bayer, Merck-Serono, and Synarc-CCBR. Dr. Provost began his career as Research Physician in Clinical Pharmacology at St Antoine University Hospital (Sorbonne University, Paris). He is a member of the Board of Directors of the Centre for Probe Development and Commercialization (CPDC), Canada. Dr. Provost holds degrees in Methodology and Statistics and Clinical Pharmacology from the University of Paris and a Doctorate in Medicine from the University of Pierre & Marie Curie, Paris.